PureTech Health plc (PRTC)
| Previous Close | 17.08 |
| Open | 17.60 |
| Bid | 16.00 x 1100 |
| Ask | 28.64 x 900 |
| Day's Range | 17.57 - 18.00 |
| 52 Week Range | 17.08 - 38.49 |
| Volume | |
| Avg. Volume | 2,945 |
| Market Cap | 490.432M |
| Beta (5Y Monthly) | 0.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023
BOSTON, December 07, 2023--PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023
- Business Wire
PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
BOSTON, November 29, 2023--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Karuna Therapeutics, Inc. (Nasdaq: KRTX) ("Karuna") announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for KarXT (xanomeline-trospium) for the treatment of schizophrenia in adults. The application has been granted a Prescription Drug User Fee Act (PDUFA) date of Septemb
- Business Wire
PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
BOSTON, November 17, 2023--PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Ph 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
